BREAKING STUDY: Nattokinase Breaks Down SPIKE PROTEIN, AMYLOID MICROCLOTS, BLOOD CLOTS, and SHRINKS ARTERIAL PLAQUE We assembled DECADES of evidence to uncover the powerful MULTI-TARGET EFFECTS of nattokinase: - Degrades spike protein - Breaks down harmful amyloid proteins - Dissolves abnormal amyloid microclots - Breaks down fibrin blood clots - Boosts the body’s natural clot-dissolving system - Shrinks arterial plaque - Lowers blood pressure - Reduces blood-clotting factors and platelet clumping Our new paper, “Proteolytic Targets and Clinical Benefits of Oral Nattokinase: Spike Protein and Amyloid Degradation, Fibrinolysis, and Cardiovascular Risk Reduction,” was produced through a collaboration between The Wellness Company and the McCullough Foundation. It represents one of the most comprehensive evaluations of nattokinase to date, uniquely integrating its proteolytic, cardiovascular, pharmacokinetic, amyloid, and spike-protein literature into a single paper. After oral dosing, nattokinase-related activity shows up in human blood and changes clotting and clot-breakdown markers within hours. Three independent labs have now shown that nattokinase-related enzymes can BREAK DOWN SPIKE PROTEIN in vitro—including purified nattokinase itself. At higher doses, human imaging studies reported about a 36% SHRINKAGE in carotid artery plaque—suggesting the effective range may begin around 6,000 FU/day. Randomized human trials also show modest BLOOD-PRESSURE reductions with nattokinase, with pooled decreases of about 3.5 mmHg systolic and 2.3 mmHg diastolic. And in long-term population studies, higher natto intake was associated with a 25% LOWER RISK of cardiovascular death and a 32% LOWER RISK of stroke death. Nattokinase has been well tolerated across human studies, with no notable adverse events reported across six randomized trials. Even 10,800 FU/day for 12 months was used in a large observational cohort without reported excess bleeding. This inexpensive, orally available enzyme holds immense promise for cardiovascular risk reduction in the post-COVID era. It now deserves large-scale clinical testing for cardiovascular risk reduction and other post-vaccination injury applications. We plan to launch some of these studies shortly. @twc_health @McCulloughFund @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly